Loading …

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our proprietary compound, ilofotase alfa, is being developed as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.